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Pathology Associated with 
Hormones of Adrenal Cortex
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Kamal V. Kanodia and Kamlesh S. Suthar
Abstract
Adrenal gland is an endocrine organ comprising of an outer cortex and inner 
medulla. These secrete various hormones that have a vital role in maintaining the 
normal homeostasis of the body. Lesions of adrenal cortex are quite common to 
encounter and most of these are related to the hormones secreted by three layers of 
adrenal cortex: the zona glomerulosa, the zona fasciculata, and the zona reticularis. 
Also it is very infrequent to encounter metastatic lesions in the adrenal glands too. 
So it is very important as a part of a clinician as well as a pathologist to know the 
pattern in which these hormones are secreted along with their physiological roles. 
Thus this chapter includes the disease that are related to excess as well as deficien-
cies of the hormones secreted by adrenal cortex. The chapter also includes various 
genetic syndromes that are associated with the disorders associated with hormones 
of adrenal cortex. The last part of the chapter includes a brief description of 
various benign as well as malignant lesions, the pathological as well as the etiologi-
cal aspects and the hormonal abnormalities associated. This chapter thus mainly 
focuses on the pathology associated with the adrenal cortex and hormones secreted 
by the various layers of adrenal cortex.
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1. Introduction
Adrenal gland consists of an outer cortex and inner medulla; the cortex is 
further subdivided into three distinct zones: the zona glomerulosa, the zona fas-
ciculata, and the zona reticularis. Mineralocorticoids (aldosterone) secreted from 
the zona glomerulosa are essential for fluid and electrolyte balance and the renin-
angiotensin-aldosterone system. The fasciculata secretes glucocorticoids (mainly 
cortisol). The zona reticularis produces steroid sex hormones called androgens. 
These hormones play an important role in maintaining the normal homeostasis of 
the body [1–3]. However, it is quite common to encounter disorders related to the 
hormones of these three layers. These disorders could be possibly due to adrenal 
cortical masses secondary to cortical hyperplasia. It is very infrequent to encounter 
metastatic lesions in the adrenal glands.
This chapter mainly focuses on the pathology related to adrenal cortex which 
includes various forms of adrenocortical hyperplasia and benign and malignant neo-
plasms of the adrenal gland which lead to various hormonal imbalances encountered 
in clinical practice. Hormonal deficiency is due to inherited glandular or enzymatic 
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disorder, destruction of pituitary gland by autoimmune disorders, infection, infarc-
tion, or others [4, 5]. The major disorders of the adrenal cortex are characterized by 
excessive or deficient secretion of each type of adrenocortical hormone.
2. Functional manifestations
The lesions of the adrenal cortex could be functional as well as nonfunctional, 
which means that patients with these lesions may exhibit clinical symptoms that 
are due to hypersecretion of hormones released. Usually cortical hyperplasia 
and adenomas are nonfunctioning. The functional syndromes associated with 
pathology of adrenal cortex are hypercortisolism (Cushing’s syndrome), adrenal 
insufficiency (Addison’s disease), hyperaldosteronism, and androgen excess (adre-
nogenital syndrome) [4–9].
3. Adrenal hyperplasia
Adrenal hyperplasia is characterized as a smooth, diffuse, bilateral enlarge-
ment of the adrenal glands, wherein the glands retain their adreniform shape. 
Hyperplasia can be either macronodular or micronodular. They are commonly 
unilateral; however bilateral cases are also observed [7, 8]. Broadly adrenal cortical 
hyperplasia can be grouped into three main categories: ACTH-dependent (adreno-
corticotropic hormone), ACTH-independent, and congenital adrenal hyperplasia 
(CAH). Cushing’s syndrome is one of the common functional manifestations of 
adrenal gland hyperplasia and therefore is discussed first [8, 10, 11].
3.1 Cushing’s syndrome
3.1.1 Definition
It is a syndrome which encompasses various clinical features due to chronic 
excess of glucocorticoids. The incidence is nearly 1–2 per 100,000 population 
per year. Harvey Cushing was the first to observe pituitary adenomas associ-
ated with hypercortisolism in 1932 [10–13]. Cushing’s syndrome, caused by 
prolonged exposure of tissues to high levels of cortisol, presents as constella-
tion of symptoms including central obesity, muscle fatigue/atrophy, hirsutism, 
infertility, osteoporosis, moon facies, dorsocervical and supraclavicular fat pads, 
and wide purple striae [8, 10, 12]. The syndrome may be ACTH-dependent or 
ACTH-independent. A fair number of cases attributed to iatrogenic causes are 
also identified. Most of the cases of Cushing’s syndrome are due to ACTH hyper-
secretion from the anterior pituitary and are associated with pituitary cortical 
adenoma. Majority of the cases, about 80–90%, show diffuse hyperplasia of the 
adrenal cortex [9, 10]. Nearly 15% of cases do present with ectopic ACTH secre-
tion associated with small cell lung carcinoma or bronchial carcinoid. Thymic 
carcinoids, pancreatic islet cell tumor, pheochromocytomas, and medullary 
carcinoma of thyroid form minor group of tumors associated with ectopic ACTH 
secretion [12]. In a study by Ejaz et al., lung tumors constituted 44.4% of all cases 
of neoplasm-related ectopic ACTH secretion causing Cushing’s syndrome [14]. 
Clinically patients with Cushing’s syndrome present with diastolic hypertension, 
hypokalemia, and edema. Hypogonadism and amenorrhea can also be seen in 
these patients which are attributed to suppression of gonadotropin secretion 
secondary to excess glucocorticoid secretion [10–14].
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3.1.2 Cushing disease
Cushing disease, resulting from a pituitary corticotropic adenoma, and rarely 
carcinoma, makes up to 80–85% of endogenous Cushing’s syndrome cases [8, 10, 15].
3.1.3 Investigating a case of Cushing’s syndrome
A two-stage test is usually recommended in a patient to rule out Cushing’s 
syndrome [8, 10, 15–17]:
1. The first group of tests are to screen for the evidence of hypercortisolism. These 
comprise urine cortisol excretion and low-dose dexamethasone suppression test.
2. The second group of tests comprise of the diagnostic tests which help to 
determine the cause of excessive production of cortisol. These are:
a. Plasma ACTH measurement: Low plasma ACTH level suggests an adrenal 
cause of the disease; however normal/high [ACTH] level suggests ectopic 
ACTH secretion or hypersecretion of ACTH from pituitary (Cushing’s 
disease).
b. High-dose dexamethasone suppression test: In this test the patient is 
administered with 2 mg of dexamethasone, 6 hourly for 48 h, following 
which plasma cortisol levels are measured. In the case of ectopic ACTH 
secretion or adrenal limited hypercortisolism, there is a failure of suppres-
sion of cortisol secretion. Also it is important to remember that cortisol is 
not suppressed with either low- or high-dose dexamethasone suppression 
in adrenal hyperplasia associated with ectopic ACTH production [18].
3.1.3.1 The 24-h urinary-free cortisol test
This investigation is used primarily for the diagnosis of hypercortisolism due 
to Cushing’s syndrome, and reference ranges for this test with respect to age are 
1.4–20 μg/24 h (3–8 years), 2.6–37 μg/24 h (9–12 years), 4–56 μg/24 h (13–17 years), 
and 3.5–45 μg/24 h in individuals ≥18 years of age. A 24-h urine sample with boric 
acid (10 g) as preservative is advisable for performing this analysis [10, 17–19].
3.1.4 ACTH-independent Cushing’s syndrome
Nearly 15–20% of Cushing’s syndrome are associated with ACTH-independent 
hypercortisolism and are secondary to a functioning adenoma or carcinoma. 
Diagnosis of ACTH-independent Cushing’s syndrome includes clinical features of 
hypercortisolism, absence of serum cortisol diurnal rhythm, elevated late-night 
cortisol levels, and incomplete suppression of cortisol production with low-dose 
dexamethasone suppression test [10, 17–20].
3.1.5  Pathological findings 
Adrenal glands from patients with Cushing’s syndrome/hyperplasia appear 
variably enlarged in size and weigh approximately 6–12 g. The cortical width is 
widened as compared to the reticulosa. The zona fasciculata usually shows nodular 
hyperplasia. Nearly 10–20% of the patients reveal bilateral nodular hyperplasia, and 
up to 30% of patients may have normal adrenal morphology [2, 20, 21].
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3.2 Primary pigmented nodular adrenocortical disease (PPNAD)
Primary pigmented nodular adrenocortical disease is a rare cause of childhood 
Cushing’s disease having female preponderance, whereas Cushing’s disease is 
common in prepubertal males [20–22]. It is the main endocrine manifestation of 
Carney complex (a multiple neoplasia syndrome caused by mutation in PRKAR1A 
gene) [23]. This is an autosomal dominant syndrome and is characterized by 
cutaneous lentigines, myxoma, schwannomas, and endocrinopathy [11, 23]. It was 
first described by Aidan Carney and co-workers in 1985. Almost 25–30% of patients 
with Carney complex have ACTH-independent Cushing’s syndrome. Cutaneous 
pigmentation is the commonest manifestation of the disease [24]. Lentigines are 
seen in most patients, and this characteristic manifestation can be used to make 
the definitive diagnosis. The name is derived from the macroscopic appearance of 
the adrenals that show characteristic small pigmented micronodules in the adrenal 
cortex. The disease typically involves bilateral adrenal glands. Grossly the adrenal 
glands may have variable size. The most characteristic finding is the presence of 
multiple brown-black pigmented cortical nodules that measure 1 mm to 3 cm in 
diameter. The adjacent cortical tissue invariable shows atrophy. These pigmented 
nodules may extend into corticomedullary junction or peri-adrenal fat [9, 11, 24].
On microscopy these tumors appear as sharply circumscribed, unencapsulated 
tumors composed of large eosinophilic lipid-poor cells similar to the zona reticularis 
arranged predominantly in trabecular growth pattern. However the nucleus appears 
enlarged, with a variable degree of pleomorphism and prominent nucleoli. There is 
prominent lipofuscin deposit. Lipid-rich fasciculata-like cells are also seen invari-
ably. The tumor may have focal areas of necrosis, mitotic activity, myelolipomatous 
change, and lymphocytic infiltrates [9, 11, 24].
3.3 ACTH-independent macronodular adrenal hyperplasia (AIMAH)
(Synonyms: ACTH-independent massive bilateral adrenal disease, massive 
macronodular hyperplasia, giant macronodular adrenal hyperplasia, macronodular 
adrenal hyperplasia, macronodular hyperplasia).
AIMAH is a disorder characterized by bilateral adrenocortical nodules, associ-
ated with ACTH-independent hypercortisolism, without any clinical features of 
pigmented nodular adrenocortical disease and histological features consistent with 
atrophic internodular cortex [25]. It is a rare cause of ACTH-independent Cushing’s 
syndrome with slightly male preponderance. The patients present usually at later 
age (average: 48 years) [24–26]. In few patients with AIMAH, ectopic expression 
and/or increased sensitivity to gastric inhibitory peptide, vasopressin receptors, 
and beta-adrenergic receptors is also seen [25].
Grossly these lesions are characterized by nodules in the adrenal cortex, ranging 
from 1 to 4.2 cm. The adrenal gland weighs approximately 16.7–218 g. The adrenal gland 
may have a large mass of cortical tissue and multiple bilateral nodules measuring up to 
5 cm. Combined adrenal gland weight of more than 300 g has also been noted (normal 
range: 8–12 g). Histology demonstrates large, yellow macronodules comprising of small 
cells with eosinophilic cytoplasm. Bilateral adrenalectomy and well-controlled gluco-
corticoid replacement is the most accepted treatment modality [2, 3, 9, 25, 26].
3.4 Congenital adrenal hyperplasia
CAH is an autosomal recessive disorder characterized by impaired steroido-
genesis finally leading to mineralocorticoid and cortisol deficiency secondary to 
reduced activity of enzymes required for cortisol biosynthesis in the adrenal cortex. 
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These patients usually present during the perinatal period with ambiguous genitalia 
in females and salt wasting in males. The milder forms of disease may present later 
with virilization at puberty or even as irregular menses. Most of the cases (nearly 
95%) are attributed to deficiency of the 21-hydroxylase enzyme [27, 28].
Abnormal growth and development, adverse effects on bone and the cardiovas-
cular system, and infertility are few long-term effects seen in these patients. These 
patients are usually managed by reducing glucocorticoid exposure and improving 
excess hormone control [29, 30].
Congenital adrenal hyperplasia can be of four forms [8–10, 27–30]:
1. Congenital adrenal hyperplasia: classical 21-hydroxylase deficiency
2. Simple virilizing congenital adrenal hyperplasia
3. Non-classic or late onset form of congenital adrenal hyperplasia
4. Congenital adrenal hyperplasia with steroidogenic acute regulatory (StAR) 
mutation
3.4.1 Congenital adrenal hyperplasia: Classical 21-hydroxylase deficiency
This form is the most common form of CAH, occurring due to 21-hydroxylase  
(21-OH) deficiency, accounting for almost 90% of the cases. It occurs with the 
frequency of 1:12000 to 1:15000 births, and nearly 75% of patients with classic 21-OH 
Multiple 
endocrine 
neoplasia (MEN) 
type 1
Adrenocortical lesions are seen in nearly 36–41% of individuals with MEN type 
I syndrome, the commonest being bilateral nonfunctioning adrenal cortical 
hyperplasia or adenoma; adrenocortical carcinoma is exceedingly rare. The 
pathogenesis of these lesions is proposed to be due to influence of locally secreted 
insulin and insulin-like growth factors and not due to menin gene mutations
Carney complex This syndrome encompasses multiple endocrine hyperplasia, with tumors of two 
or more endocrine glands, including primary pigmented adrenocortical disease 
(PPNAD), GH- and prolactin-producing pituitary adenomas, testicular neoplasms, 
thyroid adenoma or carcinoma, and ovarian cysts. This autosomal dominant 
syndrome is mapped to two genetic loci, one present on chromosome 2p16 and 
another locus at chromosome 17q22–24 encoding the PRKARIA gene [82]
Beckwith-
Wiedemann 
syndrome
This syndrome is characterized by gigantism, ear lobe pits and/or creases, 
macroglossia, and defects in the abdominal wall and is associated with chromosomal 
aberration of 11p15.5. These individuals are at higher risk of developing benign 
or malignant tumors of multiple organs, commonest being Wilms’ tumor, 
rhabdomyosarcoma, hepatoblastoma, and adrenal carcinoma
Li-Fraumeni 
syndrome
Rare, autosomal, dominant familial syndrome with high incidence of multiple 
malignancies at an early age, including breast cancer, leukemias, soft tissue 
sarcomas, gliomas, laryngeal carcinoma, lung cancer, and adrenocortical carcinoma. 
The pathogenesis of this syndrome is attributed to germ-line point mutations in 
the p53 tumor suppressor gene (chromosome 17p13) in pediatric age group with 
adrenocortical carcinoma and deletion of short arm of chromosome 17 (17p)
Familial 
adenomatous 
polyposis
This disease is an autosomal dominant disorder, characterized by the presence of 
multiple adenomatous polyps of the colon and rectum. The gene [adenomatous 
polyposis coli gene] is located at 5q21. These patients are at high risk to develop 
adrenocortical adenomas and carcinomas, the incidence being 7.4% higher than 
0.6–3.4% reported for normal population
Table 1. 
Hereditary adrenocortical tumor syndromes.
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deficiency also have defect in synthesizing aldosterone. These patients die in the neo-
natal period due to shock from salt wasting. CAH is associated with multiple tumors 
like testicular tumors arising from ectopic adrenal cortical rests, testicular and ovar-
ian Leydig cell tumor, and ovarian tumor of the adrenogenital syndrome as ovarian 
and paraovarian brown masses. Grossly the adrenal gland is marked enlarged having 
a cerebriform appearance. On cut surface the gland appears tan-brown in color. Under 
the microscope the adrenal gland reveals diffuse cortical hyperplasia. The cells are 
compactly arranged like how they are in the zona reticularis [2, 27–30].
Table 1 illustrates various syndromes associated with adrenocortical lesions [31].
4. Primary hyperaldosteronism (Conn’s syndrome)
This disease was defined first by Conn in 1955, with a prevalence of 5–13%. This 
syndrome is characterized by an inappropriate increase in production of aldoste-
rone which is relatively independent from the renin-angiotensin mechanism and is 
non-suppressible by sodium loading. This is one of the leading causes of secondary 
hypertension in hypertensive adults [32]. Patients with primary aldosteronism 
may exhibit adrenal cortical hyperplasia or adenoma in 30% of sporadic cases, and 
nearly 1% of sporadic cases may have adrenocortical carcinoma [33]. Clinically 
these patients present most commonly as normokalemic hypertension, and severe 
cases do show hypokalemia (Table 2).
S. no. Tests Procedure Interpretation
1. Postural testing • Performed after overnight 
recumbency
• IV catheter inserted at 7 AM (mea-
sure baseline aldosterone, cortisol, 
and PRA values at 8 AM)
• Ambulate the patient for 2 h
• Measure baseline aldosterone, 
cortisol, and PRA
• 30–50% of APAs respond to 
upright posture, and 20% of 
bilateral adrenal hyperplasia are 
unresponsive
• Diagnostic accuracy of 85%
2. 18-Hydroxycortico- 
sterone level
• Elevated (>100 ng/dL) in patients 
with APAs and is significantly 
lower in patients with IHA
• Diagnostic accuracy of 82%
Hybrid steroid levels (18-OHF 
and 18-oxoF) are high (3–30 times 
normal) in FH-I, normal to mildly 
elevated in FH-II (3–4 times normal, 
as in sporadic PA), and mildly to 
extremely high in FH-III (3–100 times 
normal)
3. Dexamethasone 
suppression test: 
used for patients 
with glucocorticoid-
remediable 
aldosteronism 
(GRA) as well as for 
those patients who 
do not have GRA
• 4-day dexamethasone suppression 
test (using a dosage of 0.5 mg every 
6 h)
• Measure aldosterone, renin, and 
cortisol levels—before suppression 
testing, after 2 days and then after 
4 days of testing
• Plasma cortisol suppression (i.e., 
<5 mcg/dL) is used as an index of 
the dexamethasone effect
• Patients without GRA: aldosterone 
levels typically fall by approxi-
mately 50% and return to the refer-
ence range by the end of testing
• Patients with GRA: persistent 
suppression of aldosterone levels to 
less than 4 ng/dL
• Sensitivity of 92% and a specificity 
of 100% for the diagnosis of GRA
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The aldosterone-to-renin ratio (ARR), a gold standard method to differentiate 
primary from secondary causes of hyperaldosteronism, is defined as the ratio of 
plasma aldosterone (expressed in ng/dL) to plasma renin activity (PRA, expressed 
in ng/mL/h). The cutoff value of ARR is 30 ng/dL per/mL per hour (or 750 pmol/L 
per ng/mL per hour). The principle behind this test is that as aldosterone secretion 
rises, PRA in ex vivo testing falls due to sodium retention. This negative feedback 
response should occur when the aldosterone levels are supraphysiologic for that 
individual patient, and PRA may fall well before plasma aldosterone is clearly 
increased. Primary aldosteronism is suspected if the ARR is >30 ng/dL per mL per 
hour. This method is also helpful in differentiating aldosterone-producing adenoma 
from bilateral adrenal hyperplasia [34].
4.1 Familial primary aldosteronism
Familial primary aldosteronism is mainly of three types, all of which are inher-
ited in an autosomal dominant manner [8, 10, 32, 33]:
1. Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteron-
ism): accounts for less than 1% of cases. This disorder is caused by a recombi-
nation between the CYP11B2 and CYP11B1 genes.
2. Familial hyperaldosteronism type II: nearly 3–5% cases of primary aldosteron-
ism belong to this category and are attributed to 7p22. This disorder still lacks a 
specific gene.
 4.1.1 Gross features
Grossly, the adrenal gland in cases of idiopathic hyperaldosteronism is rather 
unremarkable or may exhibit slight enlargement. The enlargement could be due to the 
presence of micronodules or macronodules. Usually, adenomas are unilateral and soli-
tary. However few cases of bilateral disease have also been reported. These adenomas 
S. no. Tests Procedure Interpretation
4. 18-Oxocortisol and 
18-hydroxycortisol 
(>100 nmol/day)
• Markedly elevated level of GRA
5. Adrenal venous 
sampling
• Test to differentiate unilateral 
disease from bilateral disease in 
patients with PA
• ACTH may be infused into a 
peripheral vein (at a dosage of 
50 mcg/h, starting 30 min before 
sampling)
• Can be performed with cosyntro-
pin stimulation
• Calculate lateralization index (LI): 
Plasma aldosterone (PAC) and 
plasma cortisol concentration (PCC) 
in both adrenal veins is determined
• The ratio of the higher (dominant) 
over the lower (non-dominant) 
PAC/PCC ratio is used for the 
assessment of lateralization of 
aldosterone hypersecretion
• Cutoff values of 4 during 
cosyntropin stimulation and of 2 
for unstimulated AVS—criteria 
to document lateralization of 
aldosterone excess
Source: [9, 10, 33, 34].
Table 2. 
Investigations.
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are mostly intra-adrenal and do not show a capsule. Few cases may reveal the presence 
of a true capsule or a pseudocapsule [2, 3, 35]. The cut surface of this tumor appears 
homogenous and golden yellow and is classically described as “canary yellow” [2]. 
Focal areas of hemorrhage or cystic changes can be present in few cases [35].
4.1.2 Microscopic features
Microscopically these adenomas appear encapsulated by compressed fibrous 
rim or fibrous “pseudocapsule.” The tumor cells are most commonly arranged in 
the form of nests or in alveolar pattern. Occasionally these cells may be arranged 
in short cords and trabeculae. Few cases may show mixed histological patterns. 
The tumor is composed of four different varieties of cells which may be present in 
varying proportions. More commonly seen are clear cells, having optically clear 
cytoplasm and centrally placed nuclei similar to those of the zona fasciculata cells; 
then there may be cells resembling to the zona glomerulosa or zona reticularis 
which appear small with compact eosinophilic cytoplasm. Then we have cells that 
are designated as “hybrid” cells. These hybrid cells have cytological features resem-
bling both the zona fasciculata and glomerulosa (Figure 1). The uninvolved portion 
of adrenal cortex reveals atrophy. This atrophy is secondary to the negative feedback 
suppression effect of the hypothalamic–pituitary axis. Spironolactone bodies which 
appear as small, intracytoplasmic eosinophilic inclusions, round to oval, measuring 
2–12 mm, are often encountered in adrenal cortical adenoma in patients on spirono-
lactone treatment. These inclusions are delineated from the surrounding cytoplasm 
by a small, clear halo [2, 7, 9, 35].
5. Adrenal insufficiency
5.1. Introduction and definition
Adrenal insufficiency was first described by Thomas Addison in 1855 and was 
popularly known as Addison’s disease. This disorder can occur either due to fail-
ure of the adrenal gland or impairment of the hypothalamic–pituitary axis [36]. 
Clinically this syndrome is characterized by weakness, fatigue, anorexia, abdominal 
pain, weight loss, orthostatic hypotension, and salt craving. Characteristic hyper-
pigmentation is seen in patients with primary adrenal failure [37]. This disease has 
been reported in three forms [7, 9, 37]:
Figure 1. 
Section from a 22-year-old patient, presented with a 2 cm mass in the right adrenal gland. Histology reveals 
adenoma with clusters of cells with enlarged lipid-rich cytoplasm (hematoxylin and eosin stain, ×200).
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1. Primary disease also known as Addison’s disease, a result of destruction of 
90% or more of the adrenocortical gland or conditions that involve decreased 
production of adrenal steroids, resulting in subnormal synthesis of aldoster-
one, cortisol, and androgens.
2. Secondary and tertiary insufficiency occurs due to deficiency of secretion 
of corticotropin (ACTH) and corticotropin-releasing hormone (CRH), 
respectively.
Most of the cases (80–90%) of primary adrenal insufficiency are caused by 
autoimmune adrenalitis. Most of the cases fall under the autoimmune polyendo-
crinopathy syndrome (60%) [1, 2, 19, 32–34]. Cell-mediated immune mechanisms 
are implicated in pathogenesis. Various antibodies have been identified, antibod-
ies against steroid 21-hydroxylase (85% cases) and autoantigens like steroid 
17α-hydroxylase and cholesterol side-chain cleavage enzyme. Other associations 
include cytotoxic T-lymphocyte antigen 4, protein tyrosine-phosphatase non-
receptor type 22, and the MHC class II transactivator. Secondary adrenal insuffi-
ciency results from any process that involves the pituitary gland and interferes with 
corticotropin secretion. Tertiary adrenal insufficiency results from processes that 
involve the hypothalamus and interfere with secretion of corticotropin-releasing 
hormone, arginine vasopressin, or both. Suppression of the hypothalamic–pitu-
itary–adrenal (HPA) axis by long-term administration of high doses of glucocorti-
coids is the most common cause [9, 36, 38].
5.2 Laboratory investigations
The patients of AI usually present with hyponatremia and hyperkalemia due to 
decreased aldosterone. Hypoglycemia also occurs due to cortisol. Decreased levels of 
this hormone also lead to an increase in lymphocytes and eosinophils, as a result of 
decreased immune-modulatory action of hydrocortisone. Measurement of baseline cor-
tisol levels between 8:00 and 9:00 AM is the test used to diagnose AI. A serum cortisol 
level of value less than 5 μg/mL favors diagnosis of AI. Stimulation test with cosyntropin 
which stimulates the cortex helps in differentiating primary and secondary AI. In this 
test 250 μg of cosyntropin is administered intramuscularly or intravenously, and serum 
cortisol is measured 30 min after infusion. Serum cortisol value of ≥18 μg/dL  
indicates a normal response. A cortisol peak <18 μg/dL confirms the diagnosis of 
AI. Serum cortisol level ≥ 100 pg/mL confirms the diagnosis of Addison’s syndrome. 
Serum cortisol value of <10 pg/mL confirms diagnosis of secondary AI [35–39].
6.  Adrenocortical carcinoma
6.1  Definition and introduction
ACC is a highly aggressive and a very rare malignancy. The incidence of this 
malignancy is approximately 0.72 per million cases per year according to the study 
by Surveillance, Epidemiology, and End Results (SEER) database [39]. The median 
age of diagnosis is usually fifth to sixth decade; however the German ACC Registry 
reports a median age at diagnosis of 46 years with a predilection for the female 
gender (female to male ratio: 1.5–2.5:1) [35, 38, 39].
Adrenocortical carcinomas (ACC) are rare tumors with an estimated annual 
inci¬dence of 0.7–2 cases by year and a global prevalence of 4–12 cases per million 
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6.2 Pathogenesis of adrenocortical carcinoma
Various mutations have been implicated in association with ACC. Most common 
are germ-line TP53 mutations, associated with childhood ACCs. The adult popula-
tion shows a prevalence of 3–7% of similar mutation. Childhood ACC can be found 
in association with Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, 
Lynch syndrome, and multiple endocrine neoplasia type 1. Of late an association 
with familial adenomatous polyposis (FAP), neurofibromatosis type 1, Werner 
syndrome, and Carney complex has also been postulated [39, 40].
6.2.1 Molecular mechanisms
In ACCs, chromosomal gains were frequently observed in regions 4q, 4p16, 
5p15, 5q12–13, 5q32-qter, 9q34, 12q13, 12q24, and 19p, and chromosomal losses were 
observed at 1p, 2q, 11q 17p, 22p, and 22q. Microsatellite studies identified frequent 
allelic losses in regions 17p13, 11q15, and 2p16 (85%, 92%, and 90% of samples, 
respectively) [41–43].
Signaling pathways involved in adrenal malignant carcinogenesis [44–47]:
• p53 signaling pathway
• Wnt/beta-catenin signaling pathway
• Insulin growth factor II (IGF-II) locus
6.2.1.1 The TP53 alterations
Protein p53, “guardian of genome,” is located at the 17p13 locus, and alterations 
in this gene have been noticed in various cancers including adrenocortical carci-
noma, more so at the somatic level. p53 gene mediates cellular response to stress, 
and adult sporadic ACCs usually reveal loss of heterozygosity at this locus (nearly 
85%) [48]. Stress leads to inhibition of degradation of p53 by E3 ubiquitin ligase 
MDM2, leading to inhibition of cell cycle arrest in response to DNA damage as well 
as apoptosis. These tumors tend to be larger and present at more advanced stage of 
tumor progression with shorter disease-free survival. Various genetic alterations 
have been reported in patients with adrenal cortex carcinoma like loss of PTTG1 
has been reported in nearly 84%, mutation in retinoblastoma protein (pRb) in 
nearly 27% cases and mutation in RB1 gene in 7% of the cases. Inactivating muta-
tions or homozygous deletions of CDKN2A have also been reported in 11–16% 
cases. High-level amplifications of CDK4 and MDM2 were reported in 2–7% ACCs 
[49–51]. It is surprising to see that majority of the TP53 mutations occur at the 
DNA-binding domain. Some tumors also have shown abnormalities in genes that 
encode for negative regulators of TP53, like PTTG1 which encodes for securin, 
noted in 84% of ACC. It is considered as a marker of poor survival [44, 46, 49].
6.2.1.2 Wnt/beta-catenin signaling pathway
Wnt family consists of highly conserved growth factors having similar amino 
acid sequences and is responsible for various developmental and homeostatic pro-
cesses [4, 44, 46–48, 51]. A prevalence of 39 and 84% has been reported by various 
authors on immunohistochemistry for β-catenin. The Wnt receptor is composed 
of members of the frizzled family and low-density lipoprotein receptor-related 
11
Pathology Associated with Hormones of Adrenal Cortex
DOI: http://dx.doi.org/10.5772/intechopen.84815
protein. β-Catenin accumulates in the cytoplasm and gets translocated into the 
nucleus and then binds with Wnt receptor leading to inhibition of the axin-adeno-
matous polyposis coli—glycogen synthase kinase 3β (GSK-3) complex. This blocks 
the phosphorylation of β-catenin, leading to increased accumulation of β-catenin 
in the cytoplasm which further translocates into the nucleus. Interaction between 
β-catenin with the T cell-specific transcription factor/lymphoid enhancer-binding 
factor-1 family of transcription factors occurs in the nucleus, thus regulating 
transcription of Wnt target genes. If Wnt stimulation of GSK-3 phosphorylating 
β-catenin does not occur, degradation by proteosomes occurs following ubiquity-
lation of this receptor. Wnt pathway has been implicated in patients with familial 
adenomatous polyposis and in the development of colorectal carcinomas as well as 
ACCs. Wnt/beta-catenin pathway can be activated in both benign and malignant 
tumors by CTNNB1 mutations and by ZNRF3 inactivation in adrenal cancer. ZNRF3 
is a recent gene that encodes a cell-surface transmembrane E3 ubiquitin ligase which 
acts as a negative feedback regulator of Wnt signaling. Recently, ZNRF3 was found 
to be the most frequently altered gene in study cohorts of ACC investigated by 
integrated genomics, with a prevalence of 21 and 19% in studies by Assié et al. and 
Zheng et al., respectively [50, 51].
6.2.1.3 Insulin growth factor II (IGF-II)
Nearly 85–90% of the adult adrenocortical carcinomas are attributed to IGF-II 
overexpression. This molecular abnormality is associated with DNA demethylation 
at IGF-II locus in most of cases. Various transcriptome studies have confirmed that 
IGF-II is the most upregulated gene in ACC [52, 53].
6.2.2 Biochemistry
ACC are the tumors characterized by adrenocortical hormone production in 
nearly 45–70% of patients. Hypercortisolism is the most common presentation of 
patients presenting with hormone excess leading to a plethora of symptoms like 
diabetes mellitus, hypertension, hypokalemia, muscle weakness/atrophy, and 
osteoporosis [40–43]. Excess of androgens which comprise nearly 40–60% of 
hormone-secreting ACCs can cause rapid-onset male pattern baldness, hirsutism, 
virilization, and menstrual irregularities in women. Estrogen production occurs in 
1–3% of male ACC patients, causing gynecomastia and testicular atrophy (through 
suppression of the gonadal axis). In the evaluation of adrenal tumors, regardless 
of size, androgen or estrogen production should always raise the suspicion of a 
malignant tumor [44].
6.2.3 Gross findings
ACCs are generally large tumors, measuring on average 10–13 cm. Only a minor-
ity of tumors are less than 6 cm (9–14%), with only 3% presenting as lesions less 
than 4 cm [2, 3, 6, 9, 35].
6.2.4 Microscopy findings
Microscopically these tumors have variable architectural patterns. The tumor 
cells are arranged in a trabecular, alveolar, or diffuse pattern. Occasionally mixed 
patterns are also noted. Some areas may also exhibit free-floating tumor cells form-
ing balls [2, 3, 6, 9, 35] (Figure 2A, B).
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Histologic criteria for malignancy in adrenal cortical tumors are assessed as 
follows [2, 3, 6, 9, 35, 43–45]:
1. High nuclear grade (grades III and IV according to the criteria of Fuhrman)
2. Mitotic rate > 5 per 50 HPF (10 HPF in each of the five areas that are most 
suspicious to be malignant)
3. Atypical mitotic figures (abnormal distribution of chromosomes or an exces-
sive number of mitotic spindles)
4. Eosinophilic tumor cell cytoplasm (>75% of tumor cells or <25% clear vacu-
olated cells resembling the normal fasciculata)
5. Diffuse architecture (>33% of the tumor forming patternless sheets of cells)
6. Necrosis (occurring in confluent nests of cells)
7. Venous invasion (endothelial-lined vessel with smooth muscle as a component 
of the wall)
8. Sinusoidal invasion (endothelial-lined vessel in the adrenal with little support-
ive tissue)
9. Capsular invasion (nests or cords of tumor extended into or through the 
capsule with the corresponding stromal reaction)
Weiss et al. proposed a scoring system which was further modified and is widely 
accepted to report adrenal cortex carcinomas. These criteria include [35, 43–45, 54] 
(Table 3).
6.2.5 Interpretation
Adrenal cortical adenoma: total score < 3.
Adrenal cortical carcinoma: total score ≥ 3.
Thus if the modified Weiss score is ≥ 3, then a diagnosis of adrenocortical 
carcinoma is given.
Figure 2. 
(A) Section from a 45-year-old patient, presented with a 13 cm mass in the left adrenal gland. Histology reveals 
clusters of cells having anisocytosis and enlarged nuclei with prominent nucleoli. The fair number of darkly 
stained atypical mitosis is also evident (hematoxylin and eosin stain, ×200). (B) Histology reveals clusters 
of cells having anisocytosis and enlarged nuclei with prominent nucleoli. The cells are separated by myxoid 
stroma. The fair number of darkly stained atypical mitosis is also evident (hematoxylin and eosin stain, ×400).
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However there are other features that may help in differentiating between 
adenomas and carcinoma. These are listed in Table 4 [35, 43–45].
7. Conclusion
Adrenal glands have an essential role in maintaining the normal hemostasis. 
However the three layers of adrenal cortex, the zona glomerulosa, zona fasciculata, 
and zona reticularis, secrete essential hormones that are involved in fluid and 
electrolyte balance, regulating renin-angiotensin-aldosterone system, production of 
glucocorticoids, and synthesis of sex hormones. These hormones play an important 
Criteria Score
Absent Present
Mitotic rate (≥6 mitotic figures/50 HPF) 0 1
Cytoplasm characteristics
[clear vs. compact (compact >75% of cells)]
0 1
Abnormal mitoses 0 1
Tumor necrosis 0 1
Invasion of the capsule 0 1
Overall score = 2 × mitotic rate + 2 × cytoplasm + abnormal mitoses + necrosis + capsular invasion.
Table 3. 
Weiss scoring for adrenocortical carcinoma.
Characteristics Adrenocortical adenoma Adrenocortical carcinoma
Macroscopy
Weight Usually less than 100 g More than 100 g
Hemorrhage +/− +++
Necrosis +/− +++
Cystic degeneration +/− +++
IHC
MIB-1 Negative Positive
Vimentin Negative Positive
Inhibin Positive Positive
Melanin Positive Positive
Calretinin Positive Positive
BCL-2 Positive Positive
C-kit Negative Positive
EMA Negative Negative
Cytokeratin Negative Negative
NSE — Positive
Synaptophysin — Positive
Chromogranin — Negative
Table 4. 
Differentiating features between adrenocortical adenoma and adrenocortical carcinoma.
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role in maintaining the normal homeostasis of the body. Various lesions in adrenal, 
benign as well as malignant, are known to cause disturbances in the internal milieu 
of our body. It is therefore essential to know the physiology as well as various types 
of disorders that can be encountered so as to define proper management of the 
patient. Also lesions of adrenal gland are attributed to various genetic abnormalities, 
knowledge of which can be implicated to study the pathogenesis and in applying this 
knowledge in prognosis as well as developing targeted therapy for these lesions.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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